Home › Funds › CULLINAN ASSOCIATES INC › VRTX

CULLINAN ASSOCIATES INC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

CULLINAN ASSOCIATES INC reported holding 50,437 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$26.4M, representing 1.98% of its reported portfolio and ranking #11 among its reported holdings. CULLINAN ASSOCIATES INC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)50.44K sh
Reported value held$26.37M
Portfolio Weight1.98%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How CULLINAN ASSOCIATES INC's VRTX position evolved

CULLINAN ASSOCIATES INC first disclosed a stake in VRTX in Q3 2023 at 61,076 shares (US$21.2M). The position peaked in Q3 2026 at 50,437 shares, worth US$26.4M. Across 13 filings, CULLINAN ASSOCIATES INC increased the stake 1 time(s), trimmed it 8 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 50,437 shares valued at US$26.4M — a reduction of -1,325 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 61.08K $21.24M New
Q4 2023 58.28K $23.71M Reduce
Q1 2024 56.28K $23.52M Reduce
Q2 2024 55.66K $26.09M Reduce
Q3 2024 54.66K $26.25M Reduce
Q4 2024 53.16K $21.41M Reduce
Q1 2025 53.11K $25.75M Hold
Q2 2025 52.01K $23.16M Reduce
Q3 2025 51.41K $20.13M Reduce
Q4 2025 51.31K $23.26M Hold
Q1 2026 51.76K $23.11M Add
Q2 2026 51.76K $25.71M Hold
Q3 2026 50.44K $26.37M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has CULLINAN ASSOCIATES INC held VRTX?

CULLINAN ASSOCIATES INC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is CULLINAN ASSOCIATES INC's current position in VRTX?

As of Q3 2026, CULLINAN ASSOCIATES INC holds 50.44K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $26.37M, representing 1.98% of its reported portfolio and ranking #11.

Has CULLINAN ASSOCIATES INC been buying or selling VRTX?

In the latest 13F filing (Q3 2026), CULLINAN ASSOCIATES INC reduced its position in VRTX. The position peaked in Q3 2026 at 50.44K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.